

CARDIOLOGY UPDATE 2006

Inflammation and Atrial Fibrillation

Anthony M. Sideris, MD, Kostas Letsas, MD

*2nd Department of Cardiology,
Evangelismos General Hospital,
Athens, Greece*

LIST OF ABBREVIATIONS:

ACEI: Angiotensin-converting enzyme inhibitors
AF: atrial fibrillation
ARB: angiotensin II receptor blockers
CRP: C-reactive protein
IL: interleukin
PUFA: omega-3 polyunsaturated fatty acids
RAAS: renin-angiotensin-aldosterone system
TNF: tumor necrosis factor

KEY WORDS: *atrial fibrillation, inflammation*

Address for correspondence:
Anthony Sideris, MD
2nd Department of Cardiology
Evangelismos General Hospital
Athens, Greece
E-mail: asideris@hol.gr

ABSTRACT

There is accumulating evidence pointing to an important association between inflammation and atrial fibrillation (AF). Elevated plasma levels of several markers of the inflammatory cascade have been shown to predict future risk of AF. Inflammation is likely to represent a novel target for both the treatment and prevention of atrial fibrillation.

INTRODUCTION

Recent advances have raised the hope of effective pharmacological or non-pharmacological treatments of atrial fibrillation (AF), and of better understanding of the pathophysiological mechanisms involved in the initiation and persistence of the arrhythmia. The pathophysiology of AF is complex and multifactorial. The underlying etiology is likely different in different patient subpopulations. The development of AF leads to many structural and electrical changes contributing to its perpetuation [1]. Atrial fibrillation also confers a prothrombotic or hypercoagulable state, which may contribute to the risk of thromboembolism [2].

Acute phase response is an innate biological response to a disturbance in homeostasis (infection, inflammation, tissue injury, neoplasm, or immune disturbance). A local reaction at the site of injury or infection leads to an activation of cytokines, specifically interleukin-1 (IL-1), tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), and interferons. Cytokines then trigger systemic responses, which include leukocytosis; increases in glucocorticoid production; increases in erythrocyte sedimentation rate, fever, activation of complement and clotting cascades and an increase in plasma levels of acute phase proteins, C-reactive protein (CRP), serum amyloid A, fibrinogen, and other proteins [3].

C-reactive protein is one of the two most abundant acute phase reactants in humans: levels rapidly increase in the circulation as a result of either trauma or infection. Manufactured in the liver and deposited in damaged tissue, CRP is found in high levels in inflammatory fluids and in both the intimal layer of the atherosclerotic aortic artery and the foam cells within the lesions of atherosclerotic plaque [4,5]. C-reactive protein stimulates mononuclear cells to release tissue factor, a protein that is central to the initiation of coagulation reactions, complement activation, and the neutralization of platelet-activation factor. Together, these reactions promote a thrombotic response [6]. C-reactive protein has been traditionally thought of as a bystander marker of vascular inflammation, without playing a direct role in the inflammatory process. However, recent evidence suggests that CRP may contribute directly to the proinflammatory state [7,8]. An increased CRP plasma concentration is strongly associated with the

risk of serious cardiovascular events, being the measure of a generalized atherosclerotic inflammatory process [9].

INFLAMMATORY MARKERS

There is accumulating evidence pointing to an important association between inflammation and AF. Of all the plasma markers of inflammation, CRP has been the most extensively investigated in clinical studies. The first observation relating inflammation to AF after cardiopulmonary bypass surgery was made in 1997 by Bruins et al. They proposed a direct link between inflammation and AF by observing an increased frequency of AF after coronary artery bypass surgery. The peak incidence of AF occurred on the 2nd-3rd postoperative day, coinciding with the maximal elevation of CRP [10].

Inflammatory changes have also been reported in patients with non-postoperative AF. Marked inflammatory alterations have been observed in atrial specimens obtained from patients with isolated persistent AF [11]. Furthermore, Chung, et al found that CRP levels were significantly higher in patients with paroxysmal and chronic AF than in normal controls, and that the level was higher in the chronic AF than in the paroxysmal AF group. Thus, they showed that inflammation is involved in the onset of AF. However, they stated that whether inflammation is a consequence or a cause of AF remains unknown [12]. Some authors suggested the role of inflammation in atrial remodelling which promotes the initiation and perpetuation of AF [13]. It has been shown that plasma CRP concentration is higher in patients with AF, both paroxysmal and persistent, compared with the general population [12-14]. An increased baseline CRP level is also a risk factor for the development of AF during a long-term follow-up period [15]. In one study, the combination of microalbuminuria and an elevated hs-CRP increased the risk of subsequent AF development by up to four-fold [16]. It has also been demonstrated that CRP represents a robust and significant predictor of early AF relapse after successful cardioversion in patients with AF even after adjustment for multiple risk factors, such as hypertension and coronary artery disease [14,17,18]. Interestingly, two recent studies indicated that CRP relates to the left atrial size and AF duration before cardioversion, providing evidence of an association between inflammation and atrial structural remodelling [19,20].

Another established marker of the inflammatory cascade is IL-6. IL-6 is a circulating cytokine produced by monocytes, macrophages, lymphocytes and endothelial cells. IL-6 can induce a prothrombotic state by increasing expression of fibrinogen, tissue factor, factor VIII and von Willebrand factor, as well as by activating endothelial cells and increasing platelet production [21]. IL-6 is the main hepatic stimulus for CRP production [22]. Higher blood levels of IL-6 and fibrinogen after coronary artery bypass were observed in patients who de-

veloped AF after surgery. The -174G/C Interleukin-6 promoter gene variant appeared to modulate the inflammatory response to surgery and to influence the development of postoperative AF, suggesting an inflammatory component of postoperative atrial arrhythmias and a genetic predisposition to this complication [23]. Similar data have recently been reported for patients with non-postoperative AF. Several studies found increased levels of IL-6 in patients with AF compared with healthy controls [17,19,24-26].

Tumor necrosis factor- α (TNF- α) is a multifunctional circulating cytokine derived from endothelial and smooth muscle cells as well as macrophages [27,28]. TNF, along with interferon- γ and IL-1, stimulates IL-6 production by smooth muscle cells [29,30]. Sata et al measured TNF- α and other indices of inflammation during episodes of paroxysmal AF and after the restoration of sinus rhythm in the same patients, to clarify the relationship between inflammation and the onset of AF. Levels of hs-CRP, IL-6, and TNF after cardioversion were significantly higher than those in controls. Furthermore, the levels of these indices did not differ significantly even at 24 hours and 2 weeks after cardioversion. They concluded that inflammation is a causative agent of paroxysmal AF [25].

A prothrombotic or hypercoagulable state has been described in AF, which leads to the high risk of stroke and thromboembolism in this condition [1,31-33]. There is an apparent link between thrombogenesis and inflammation [34-36]. This supports the concept that the observed inflammation in AF increases the risk of thromboembolism as has been demonstrated for atherosclerotic models. High plasma IL-6 levels have been shown to be an independent predictor of stroke and the composite end point of stroke and death in a prospective study of patients with AF, suggesting that inflammation in AF may predict a poor prognosis. Interestingly, trends toward increased risk with high plasma CRP did not reach statistical significance [37]. Similarly, Thambidorai et al were able to demonstrate in 104 patients with AF that clinical and transoesophageal risk factors for stroke were greater for patients with elevated CRP compared with those with normal levels [38]. This observation is consistent with the results reported by Conway et al [26]. A risk score for stroke in AF has been correlated with IL-6 [24]. Given the evidence so far, the association between markers of inflammation and AF suggest that inflammation plays a role in the pathogenesis of this arrhythmia.

ANTI-INFLAMMATORY INTERVENTIONS

Drug therapy to prevent AF has traditionally targeted atrial electrophysiological mechanisms; however, the proarrhythmic effects of such drug therapy have limited its safety. An alternative strategy for the prevention of AF would be to prevent inflammation.

GLUCOCORTICOIDS

Glucocorticoids are used to treat a wide variety of inflammatory diseases. The first observation of a favourable effect of corticosteroid treatment on AF was made in 2000 by Yared et al [39]. Patients undergoing elective coronary or valvular heart surgery were randomized to receive dexamethasone or placebo after induction of anesthesia. They found that, compared with placebo, patients receiving dexamethasone had a lower incidence of new-onset atrial fibrillation during the first 3 days postoperatively. However, in another randomized, double-blinded, placebo-controlled study, dexamethasone failed to decrease the incidence of postoperative atrial fibrillation [40]. Dernellis and Panaretou demonstrated that the use of low dose glucocorticoids not only improved the efficacy of sinus rhythm maintenance postcardioversion but was also followed by a fall in CRP levels [14].

STATINS

The use of HMG-CoA reductase inhibitors (statins) in the treatment of dyslipidemia has been shown to improve survival and significantly reduce the appearance of cardiac events, both in primary and secondary prevention [41,42]. Statins also have so-called pleiotropic effects, which improve endothelial function, reduce inflammation, enhance angiogenesis and vasculogenesis, limit oxidative processes, stabilize atherosclerotic plaques, and inhibit the thrombogenic response [43,44].

An association between inflammation and AF is undoubtedly present. Therefore, therapeutic approaches targeting inflammation and oxidative stress may exert favourable effects on the risk of AF. Statins have both antiinflammatory and antioxidant properties [45,46]. In an animal study, simvastatin attenuated AF promotion by atrial tachycardia in dogs, an effect not shared by antioxidant vitamins [47]. The available evidence tends to prove that statin therapy, which poses anti-inflammatory properties and reduces CRP levels protects patients with coronary artery disease from developing AF. This effect appears to be distinct from its cholesterol lowering ability [48,49]. Hanna et al analyzed data from Advancent, a large multicenter registry of patients with reduced left ventricular ejection fraction, to explore the relationship between lipid-lowering therapy and AF. Lipid-lowering therapy was strongly protective against the development of AF. This benefit appeared to be independent of the lipid profile and additive to the protective effects of β -blockade and angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) [50]. Similar benefits have been observed in patients undergoing coronary artery bypass grafting [51]. C-reactive protein lowering with atorvastatin appears to be effective in eliminating PAF during daily life in a significant proportion

of patients [52]. However, in a recent post hoc analysis of a large randomized clinical trial, MIRACL study, intensive statin treatment did not appear to prevent new AF in the 16 weeks following acute coronary syndrome [53]. Tveit et al also reported that pravastatin did not reduce the recurrence rate of AF after electrical cardioversion [54]. Further clinical research will determine whether the more widespread use of statins will become an important component of the treatment of patients with atrial fibrillation.

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEI) AND ANGIOTENSIN II RECEPTOR BLOCKERS (ARB)

Activation of the rennin-angiotensin-aldosterone system (RAAS) has been implicated in the pathogenesis of a broad spectrum of cardiovascular diseases [55]. Equally, interruption of the RAAS by either ACEI and/or ARBs is highly effective in reducing the known cardiovascular outcomes of these diseases [56]. In AF, the RAAS can influence both electrical and structural remodelling associated with this arrhythmia [55]. There is evidence to date in support of a role for RAAS activation as an important factor in the association between inflammation and AF. Experimental studies have revealed that angiotensin II possesses several proinflammatory properties, such as the activation of various inflammatory mediators (eg, CRP, TNF, IL-6, monocyte chemoattractant protein, nuclear factor-kappaB and nuclear factor-alpha), as well as stimulating the recruitment and infiltration of neutrophils [57,58]. Furthermore, Cardin et al were able to demonstrate that increased atrial expression of angiotensin II is linked with increased atrial cell death and leukocyte infiltration, again supporting a potential link between the RAAS, inflammation and AF [59]. RAAS blockade elicits anti-inflammatory and anti-aggregatory effects in patients with coronary artery disease and prevents atherosclerosis and vascular inflammation [60]. Both ACE-inhibitors and ARBs appear to have significant anti-inflammatory actions [61].

Given the potential role of the RAAS in AF, it would be rational to suspect that RAAS blockade by ACE inhibitors and ARBs may have beneficial effects in AF. Among patients enrolled in the SOLVD study of enalapril in left ventricular dysfunction, only 5.4% of the patients on enalapril experienced AF compared with 24% in the placebo arm. In multivariate analysis enalapril was the strongest predictor of reduced AF incidence [62]. Healey et al conducted a meta-analysis of the available 11 randomized clinical studies on RAAS blockade and AF, which included a total of 56,308 patients. They concluded that ACE inhibitors/ARBs reduced the overall risk of AF by 28% ($P=0.0002$). Furthermore, the reduction in AF was similarly independent of whether an ACE inhibitor or an ARB was the main drug group used (ACE inhibitors: 28%,

P=0.01; ARBs: 29%, P=0.00002) [63]. More impressive are the data from CHARM and Val-HeFT studies, showing an overall 44% relative risk reduction in the development of AF among patients with heart failure (P=0.007). The authors also noted a clear relationship between worsening heart failure (and greater activation of the RAAS system) and greater AF prevention [64,65]. Unfortunately, none of the randomized AF trials analyzed levels of known inflammatory markers simultaneously with the observed beneficial effects in preventing either new onset AF or arrhythmia relapse.

POLYUNSATURATED FATTY ACIDS (PUFA)

Evidence from epidemiologic and clinical prevention trials suggest that the omega-3 polyunsaturated fatty acids (n-3 PUFAs) may have a significant role in protecting against death from cardiovascular disease [66-69]. The n-3 PUFAs have been shown to exert a range of anti-inflammatory actions which include decreased production of arachidonic acid-derived prostaglandins and leukotrienes, decreased production of inflammatory cytokines, decreased expression of adhesion molecules and decreased expression of degrading proteinases that can erode plaque caps [70,71]. As AF has an important inflammatory component and n-3 PUFAs are potent anti-inflammatory agents, recent attention has focused on the possible antiarrhythmic effects of PUFA. In cultured rat atrial myocytes, n-3 fatty acids reduce induced asynchronous contractile activity, suggesting that n-3 fatty acids from fish may have antiarrhythmic effects on atrial muscle [72]. Besides direct electrophysiological effects, it has been proposed that the anti-inflammatory effects of these natural compounds may favourably affect atrial remodelling [73]. In a large, prospective study among elderly adults, greater consumption of tuna or other broiled or baked fish was associated with lower risk of incident AF. This observed relationship persisted after adjustment for a variety of demographic, clinical, lifestyle, laboratory, and dietary characteristics, including preceding myocardial infarction and congestive heart failure [74]. However, in the Danish Diet, Cancer, and Health study consumption of n-3 fatty acids from fish was not associated with a reduction in risk of atrial fibrillation or flutter [75].

ASCORBIC ACID

Antioxidant interventions with vitamin C might have an impact against AF-associated inflammation. Carnes et al were the first to show that an antioxidant intervention with vitamin C ameliorates atrial electrical remodeling in experimental animals and significantly reduces the incidence of postoperative AF in patients undergoing coronary bypass

surgery [76]. In a subsequent report examining 46 patients, Korantzopoulos et al demonstrated that treatment with vitamin C reduced the early recurrence of AF after cardioversion of persistent AF. In the vitamin C group, CRP levels were lower on the seventh day postcardioversion when compared with baseline [77].

CONCLUSION

Inflammation plays an important role in the development of AF [78-80]. Therefore inflammation may be a new therapeutic target in the management of AF. More studies are needed to clarify this important issue.

REFERENCES

1. Levy S, Sbragia P. Remodelling in atrial fibrillation. *Arch Mal Coeur* 2005; 98:308-12.
2. Lip GY. Does atrial fibrillation confer a hypercoagulable state? *Lancet* 1995; 346:31-34.
3. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. *Biochem J* 1990; 265:621-636.
4. Ballou SP, Kushner I. C-reactive protein and the acute phase response. *Adv Intern Med* 1992; 37:313-336.
5. Reynolds GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. *Arch Pathol Lab Med* 1987; 111:265-269.
6. Pepys MB. The acute phase response and C-reactive protein. In: Weatherall DJ, Ledingham JGG, Warrell DA, eds. *Oxford Textbook of Medicine*. New York, NY: Oxford University Press; 1996:1527-1533.
7. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. The major receptor for C-reactive protein on leukocytes is fcγ receptor II. *J Exp Med* 1999; 190:585-590.
8. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. *Circulation* 2000; 102:2165-2168.
9. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor. *Circulation* 1999; 100:96-102.
10. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. *Circulation* 1997; 96:35428.
11. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. *Circulation* 1997; 96:1180-1184.
12. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias. *Circulation* 2001; 104:2886-91.
13. Korantzopoulos P, Kolettis T, Siogas K, et al. Atrial fibrillation and electrical remodeling: the potential role of inflammation

- and oxidative stress. *Med Sci Monit* 2003; 9:RA225-229.
14. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. *Acta Cardiol* 2001; 56:375-80.
 15. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. *Circulation* 2003; 108: 3006-10.
 16. Asselbergs FW, van den Berg MP, Diercks GF, van Gilst WH, van Veldhuisen DJ. C-reactive protein and microalbuminuria are associated with atrial fibrillation. *Int J Cardiol* 2005; 98: 73-77.
 17. Conway DS, Buggins P, Hughes E, Lip GY. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. *Am J Cardiol* 2004; 94:50810.
 18. Malouf JF, Kanagala R, Al Atawi FO, et al. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. *J Am Coll Cardiol* 2005; 46(7):1284-7.
 19. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. *Am J Cardiol* 2005; 95:764-767.
 20. Watanabe T, Takeishi Y, Hirono O, Itoh M, et al. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. *Heart Vessels* 2005; 20:45-49.
 21. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. *Br J Hematol* 2001; 115:3-12.
 22. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. *Biochem J* 1990; 265:621-636.
 23. Gaudino M, Andreotti F, Zamparelli R, Castelnuovo A, et al. The 174G/C Interleukin-6 Polymorphism Influences Postoperative Interleukin-6 Levels and Postoperative Atrial Fibrillation Is Atrial Fibrillation an Inflammatory Complication? *Circulation* 2003; 108[suppl II]:II-195-II-199.
 24. Roldan V, Marin F, Martinez JG, Garcia-Herola A, et al. Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. *Am J Cardiol* 2005; 95:881-882.
 25. Sata N, Hamada N, Horinouchi T, Amitani S, et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? *Jpn Heart J* 2004; 45:441-445.
 26. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. *J Am Coll Cardiol* 2004; 43: 2075-2082.
 27. Warner SJ, Libby P. Human vascular smooth muscle cells: target for and source of tumor necrosis factor. *J Immunol* 1989; 142:100-109.
 28. Barath P, Fishbein MC, Cao J, Berenson J, et al. Detection and localization of tumor necrosis factor in human atheroma. *Am J Cardiol* 1990; 65:297-302.
 29. Ng SB, Tan YH, Guy GR. Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1. *J Biol Chem* 1994; 269:19021-19027.
 30. Sanceau J, Kaisho T, Hirano T, Wietzerbin J. Triggering of the human interleukin-6 gene by interferon-g and tumor necrosis factor-a in monocytic cells involves cooperation between interferon regulatory factor-1, NF kB, and Sp1 transcription factors. *J Biol Chem* 1995; 270:27920-27931.
 31. Lip GYH, Lowe GDO, Rumley A, et al. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. *Br Heart J* 1995; 73:527-33.
 32. Roldan V, Marin F, Marco P, et al. Hypofibrinolysis in atrial fibrillation. *Am Heart J* 1998; 136:956-60.
 33. Conway DSG, Chin BSP, Pearce LA, et al. Plasma von Willebrand factor and soluble P-Selectin as indices of endothelial damage and platelet activation in 1321 patients with non-valvular atrial fibrillation: relationship to stroke risk factors. *Circulation* 2002; 106:1962-2967.
 34. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. *Thromb Haemost* 2001; 86:746-56.
 35. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. *Br J Hematol* 2001; 115:3-12.
 36. Joseph L, Fink LM, Hauer-Hensen M. Cytokines in coagulation and thrombosis: a preclinical and clinical review. *Blood Coagul Fibrinol* 2002; 13:105-16.
 37. Conway DSG, Buggins P, Hughes E, Lip GYH. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. *Am Heart J* 2004; 148: 462-466.
 38. Thambidorai SK, Parakh K, Martin DO, et al. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. *Am J Cardiol* 2004; 94: 8057
 39. Yared JP, Starr NJ, Torres FK, Bashour CA, et al. Effects of single dose, postinduction dexamethasone on recovery after cardiac surgery. *Ann Thorac Surg* 2000;69:1420-1424
 40. Halvorsen P, Raeder J, White PF, Almdahl SL, et al. The effect of dexamethasone on side effects after coronary revascularization procedures. *Anesth Analg* 2003; 96(6):1578-83
 41. Shepherd J, Cobe SM, Ford I, Isles CJ, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med* 1995; 333:1301-7.
 42. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 205,536 high-risk individuals: a randomized placebo controlled trial. *Lancet* 2002;360:7-22.
 43. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Arterioscler Thromb Vasc Biol* 2001;21:1712-9
 44. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects of statins: Lipid reduction and beyond. *J Clin Endocrinol Metab* 2002; 87:1451-8.
 45. Weitz-Schmidt G. Statins as anti-inflammatory agents. *Trends Pharmacol Sci* 2002; 23:482-486.
 46. Shishebor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific in-

- flammatory pathways. *Circulation* 2003; 108:426–431.
47. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of Simvastatin and Antioxidant Vitamins on Atrial Fibrillation Promotion by Atrial-Tachycardia Remodeling in Dogs. *Circulation* 2004; 110:2313-2319.
 48. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. *Am J Cardiol* 2003; 92:1379-1383.
 49. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. *Circulation* 2001; 103:1191-3.
 50. Hanna IR, Dudley SC Jr, King-Hageman D, Bush H, et al. Lipid-lowering therapy reduces the prevalence of atrial fibrillation (Abstract). 2005 Heart Rhythm Society Scientific Sessions, May 4–7, 2005, New Orleans, LA, pp. 1–34.
 51. Marin F, Pascual DA, Roldan V, Arribas JM, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. *Am J Cardiol* 2006; 97:55-60
 52. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. *Am Heart J* 2005; 150: 1064e7–1064e12.
 53. Schwartz GG, Olsson AG, Chaitman B, Goldberger J, et al. Effect of intensive statin treatment on the occurrence of atrial fibrillation after acute coronary syndrome: an analysis of the MIRACL Trial. *Circulation* 2004; 110(Suppl III):740.
 54. Tveit A, Grundtvig M, Gundersen T, Vanberg P, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. *Am J Cardiol* 2004; 93:780–782
 55. Freestone B, Beevers DG, Lip GY. The renin–angiotensin–aldosterone system in atrial fibrillation: a new therapeutic target? *J Hum Hypertens* 2004; 18:461–465.
 56. Choudhury A, Varughese G, Lip GYH. Targeting the Renin Angiotensin Aldosterone System in Atrial Fibrillation: a shift from electrical to structural therapy? *Exp Opin Pharmacother* 2005; 2005; 6:2193-207.
 57. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. *Eur Heart J* 2005; 26: 2083-2092.
 58. Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? *Med Sci Monit* 2005; 11: RA155–RA162.
 59. Cardin S, et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. *Cardiovasc Res* 2003; 60:315–325.
 60. da Cunha V, Tham DM, Martin-McNulty B, Deng G, et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. *Atherosclerosis* 2005; 178:9–17.
 61. Schieffer B, Bunte C, Witte J, Hoepfer K, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. *J Am Coll Cardiol* 2004; 44:362–368.
 62. Vermes E, Tardif J, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular infarction: insight of the Studies of Left Ventricular Dysfunction (SOLVD) Trials. *Circulation* 2003; 107:2926-2931.
 63. Healey JS, Baranchuk A, Crystal E, Morillo CA, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. *J Am Coll Cardiol* 2005; 45:1832–1839.
 64. Swedberg K. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: results from the CHARM study (abstr). *J Am Coll Cardiol* 2004; 23(Suppl A):222A.
 65. Maggioni AP, Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). *Am Heart J* 2005; 149:548–557.
 66. Rodriguez BL, Sharp DS, Abbott RD, et al. Coronary heart disease/atherosclerosis/myocardial Infarction: fish intake may limit the increase in risk of coronary heart disease morbidity and mortality among heavy smokers: The Honolulu Heart Program. *Circulation* 1996; 94: 952-6.
 67. Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. *N Engl J Med* 1995; 332:977-83.
 68. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. *Lancet* 1999; 354:447-55.
 69. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. *Circulation* 2002; 105:1897-1903.
 70. A joint British Journal of Cardiology and H.E.A.R.T UK round table meeting held at the National Heart and Lung Institute, 18th November 2003. Omega-3 Polyunsaturated Fatty Acids: Mechanisms and Clinical Applications Explored. *Br J Cardiol* 2004; 11(1):16-21.
 71. Thies F, Garry JM, Yaqoob P, Perkasem K, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. *Lancet* 2003; 361(9356): 477-85
 72. Jahangiri A, Leifert WR, Patten GS, et al. Termination of asynchronous contractile activity in rat atrial myocytes by n-3 polyunsaturated fatty acids. *Mol Cell Biochem* 2000; 206:33–41.
 73. Korantzopoulos P, Kolettis TM, Goudevenos JA. The anti-inflammatory and antioxidant effects of long-chain n-3 fatty acids or oil-rich fish may favorably affect atrial remodeling in atrial fibrillation. *Med Hypotheses* 2005; 64:1245–1246.
 74. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, et al. Fish intake and risk of incident atrial fibrillation. *Circulation* 2004; 110:368–373.
 75. Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. *Am J Clin Nutr* 2005; 81:50–54.
 76. Carnes CA, Chung MK, Nakayama T, Nakayama H, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodelling and decreases the incidence of postoperative atrial fibrillation. *Circ Res* 2001; 89:e32–e38.
 77. Korantzopoulos P, Kolettis TM, Kountouris E, Dimitroula V, et al. Oral vitamin C administration reduces early recurrence

- rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. *Int J Cardiol* 2005; 102:321-326.
78. Boos CJ, Lip GY. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. *J Hum Hypertens* 2005; 19:855-859.
79. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? *Eur Heart J* 2006; 27:136-149.
80. Boos CJ, Lip GY. Prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. *J Am Coll Cardiol* 2006; 47:889-890.